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The V3 loop of the HIV-1 envelope (Env) protein elicits a vigorous, but largely non-
neutralizing antibody response directed to the V3-crown, whereas rare broadly neutralizing
antibodies (bnAbs) target the V3-base. Challenging this view, we present V3-crown directed
broadly neutralizing Designed Ankyrin Repeat Proteins (bnDs) matching the breadth of V3-
base bnAbs. While most bnAbs target prefusion Env, V3-crown bnDs bind open Env con-
formations triggered by CD4 engagement. BnDs achieve breadth by focusing on highly
conserved residues that are accessible in two distinct V3 conformations, one of which
resembles CCR5-bound V3. We further show that these V3-crown conformations can, in
principle, be attacked by antibodies. Supporting this conclusion, analysis of antibody binding
activity in the Swiss 4.5 K HIV-1 cohort (n= 4,281) revealed a co-evolution of V3-crown
reactivities and neutralization breadth. Our results indicate a role of V3-crown responses and
its conformational preferences in bnAb development to be considered in preventive and
therapeutic approaches.
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HIV-1 entry depends on the interaction of the variable loop3 (V3) of its envelope (Env) protein with an HIV co-receptor, commonly CCR5 or CXCR41–3. In line with its
critical function in entry, the three sections of the V3 - (i) the base
(residues 296–299 and 327–331 within the HxB2 reference
strain), (ii) the stem (residues 300–303 and 321–326), and (iii) the
crown (residues 304–320)4,5 - are largely conserved, making the
V3 loop a potential prime target for neutralizing antibodies
(nAbs), inhibitors and vaccine approaches. Yet, V3 is effectively
shielded from antibody recognition by interaction with the vari-
able loops 1 and 2 (V1V2)6–10. Conformational changes in the
Env trimer upon CD4 receptor binding trigger a displacement of
V1V2, lifting its trimer stabilizing function and enabling V3 to
interact with the HIV co-receptors. The ensuing trimer opening
exposes highly neutralization sensitive sites within the V3-
crown5,9,11,12. However, the window of accessibility is normally
not sufficient to allow V3-crown specific antibodies to effectively
block infection. Prototypically, a vigorous V3 antibody response
is elicited in almost all HIV-1 infected individuals, but bears little
to no neutralization activity as it is mostly constituted of V3-
crown Abs9,13,14.
Rare broadly neutralizing antibodies (bnAbs) targeting V3
overcome the access restriction on the trimer by binding to the
conserved V3-base, involving the GDIR motif and surrounding
glycans15,16. Considering the crucial function and conservation of
the V3-crown, V3-crown inhibitors that can bypass
V1V2 shielding could have immense therapeutic potential. If
V1V2 shielding is artificially released, V3-crown Abs display
extreme potency and breadth, thus confirming that accessibility,
not specificity is the limiting factor9. Although a few cross-
neutralizing V3-crown specific neutralizing Abs have been iden-
tified, overall they lack breadth compared to V3-base directed
bnAbs15–20. The properties that distinguish cross-neutralizing
V3-crown Abs from non-neutralizing V3 Abs are currently not
fully understood. A capacity to recognize the V3-crown in dis-
tinct conformations has been proposed as a potential
requirement5,19,21–25.
Using the Designed Ankyrin Repeat Proteins (DARPin)
technology26, we previously developed the V3-crown specific
DARPin 5m3_D12 that shares features with cross-neutralizing
V3-crown Abs and has activity against difficult to neutralize
(Tier-2) strains of HIV-1 subtype B27. Notably, 5m3_D12 par-
tially by-passes V1V2 shielding, suggesting that generation of
DARPin based broadly neutralizing V3-crown inhibitors may be
possible. DARPins are based on a small rigid binding-protein
scaffold, providing high target affinity and specificity for biome-
dical applications26,28–30. Due to their rigid binding surface
complementary to folded protein domains, DARPins often bind
in a conformation-specific manner26,27,31. Exemplary for this,
5m3_D12 displays a strong binding preference for a specific V3-
crown conformation27. Identification of novel broadly neutraliz-
ing V3 DARPins may thus reveal V3 conformations that are
relevant for infection. Building on the discovery of 5m3_D12, we
here exploit the DARPin technology in order to define con-
formational states of the V3-crown that are targetable for broad
neutralization.
Results
Broad neutralization via the V3-crown is possible. Starting
from highly diverse DARPin libraries we performed five inde-
pendent DARPin selections (Selections A-E) by Ribosome
Display32,33. In these selections we utilized different combinations
of Env-derived panning targets with the aim to select V3-specific
DARPins with high neutralization breadth (Fig. 1a and Supple-
mentary Figs. 1, 2 and 3a, b). From each ribosome display
selection pool, individual DARPin clones were subsequently
screened for binding to their respective selection targets and
tested for cross-neutralizing activity (Fig. 1a and Supplementary
Fig. 2). The best neutralizers of each selection were retained,
yielding a final set of six DARPins (Supplementary Fig. 2b).
V3 specificity was confirmed by the binding to linear V3 peptide
(Fig. 1a). Sequence analysis showed that the selected DARPins
were distinct clones that were neither related to each other, nor to
the previously identified cross-neutralizing DARPin 5m3_D1227
(Supplementary Fig. 4a). All six selected DARPins were mono-
meric in solution (Supplementary Fig. 4b).
Subsequent analysis of neutralization breadth on multi-clade
virus panels (Fig. 1, Supplementary Figs. 5a, 6 and Supplementary
Data 1) identified three DARPins with exceptional breadth. They
were accordingly named broadly neutralizing DARPins (bnDs).
V3-crown specific DARPins 63_B7, SE4, and 5m3_D12 were less
broad (Fig. 1a), but still surpassed the breadth of the prototypic
V3-crown monoclonal antibody (mAb) 447-52D34,35. bnD.1,
bnD.2 and bnD.3 reached 63%, 90 and 75% breadth, respectively,
on a 40-virus multi-clade panel (Fig. 1b and c, Supplementary
Data 1). Notably, these bnDs matched or even exceeded the
breadth of the V3-base bnAbs PGT121 (70%), PGT128 (75%),
and PGT135 (30%), however, without reaching their potency. V3-
crown nAbs F425-B4e8, 3074 and DH75319 showed extended
breadth when probed at concentrations equivalent to the bnDs,
but were outperformed by bnD.2 and bnD.3 (Fig. 1c, d).
Neutralization fingerprint analysis showed a strong positive
correlation between the three bnDs, but not with V3-glycan
bnAbs or V3-crown mAbs that, similar to bnDs, have lower
potency (Fig. 1e and Supplementary Data 2). Modest significant
correlations were observed between bnD.1 and the V3 mAb 3074,
and between bnD.3 and 3074, the CD4bs mAb b12 and the
interface bnAb PGT151 (Supplementary Data 2). Collectively,
this suggests that the V3-crown specific bnDs form a novel class
of broadly neutralizing agents.
Broadly neutralizing V3-crown DARPins access V3 on Env
post CD4 engagement. Since the V3-crown is well shielded in the
closed prefusion conformation of the native Env trimer, inhibi-
tors that interact with the V3 must either be able to bypass
V1V2 shielding or access the V3 during the entry process, when
V1V2 is displaced upon CD4 engagement. We therefore probed
the capacity of bnDs to bind native Env of the Tier-2 strain JR-FL
expressed on 293-T cells, in the presence or absence of sCD4
(Fig. 2a and Supplementary Fig. 7). All V3-crown DARPins
lacked the ability to bind native Env, unless triggered by sCD4.
DARPin binding increased with higher concentrations of sCD4,
suggesting that the virus-neutralizing capacity of the V3-crown
bnDs lies in their ability to access V3 post CD4 triggering.
To rate the dependency on an open Env conformation, we
compared the capacity of bnDs and prototypic V3-crown directed
mAbs (F425-B4e8, 3074, DH753, 2219, 10A37, 1–79 and 447-
52D) to neutralize wild-type (wt) and corresponding V1V2-
deleted viruses (Supplementary Figs. 5b, 8, Supplementary
Data 4). The gain in neutralization potency in the absence of
V1V2 was dramatic for mAbs (ranging from 922 to 9,708 fold
difference in geometric mean IC50 ratio (wt-Env/ΔV1V2-Env),
but comparatively modest for bnDs (geometric mean IC50
difference of 30-, 15-, and 184-fold for bnD.1, bnD.2 and
bnD.3, respectively).
Thus, despite their dependence on trimer opening, the V3-
crown bnDs appear to have a considerable capacity to bypass
V1V2 shielding. Opening of the trimer upon CD4 engagement
occurs gradually with V1V2 retaining some shielding activity36.
In line with this model, the V3 antibodies gained substantially
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Fig. 1 Selection of V3-crown reactive broadly neutralizing DARPins (bnDs). a Scheme of the selection workflow to identify V3-crown-reactive
neutralizing DARPins. For details on panning, ribosome display selections, and the screening procedure, see Supplementary Fig. 1 and 2 as well as the
Materials and Methods section. The right panel depicts V3-crown binding and neutralizing activity of the top six neutralizing DARPins and the reference
DARPin 5m3_D12 selected for follow-up experiments (magenta). V3-crown nAbs (black) and V3-base bnAbs (blue) are shown for comparison. V3-crown
binding is depicted as 50% effective concentration (EC50) (nM) derived by ELISA. Bars indicate the geometric mean EC50 values from three independent
replicates (circles). Error bars depict the geometric standard deviation (SD). The neutralization breadth-potency plot is based on results from a multi-clade
18-virus panel (maximum concentrations probed: DARPins (10,000 nM or 20,000 nM) and mAbs (167 nM (= 25 μg/ml, commonly used for mAbs in this
type of assay)) Supplementary Data 1). The geometric mean of 50% inhibitory concentration (IC50) values in a and c were calculated over all sensitive
strains. b Extended neutralization analysis of bnDs and nAbs on a 40-virus panel (Supplementary Data 1). IC50 values (geometric mean of 1-5 independent
replicates) are shown. Minimum (5 nM: only for mAbs 3074, DH753 and F425-B4e8) and maximum concentrations of DARPins (10,000 nM) and mAbs
(10,000 nM or 167 nM (=25 μg/ml) probed are indicated by dashed lines. Viruses not neutralized are shown as dots above the dashed lines. Colors of
individual data points indicate virus clade. c Neutralization breadth-potency plot summarizing the data in b. d Neutralization breadth of V3-crown bnDs and
nAbs depending on their concentration according to data in b. e Dendrogram based on Spearman correlation (Supplementary Data 2) and single linkage
hierarchical clustering depicting the similarity of neutralization fingerprints on the 40-virus panel for bnDs and a range of bnAbs and nAbs with different
epitope specificity.
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more than bnDs from V1V2 deletion, suggesting that bnDs may
already access the V3 at an earlier stage of the CD4 triggering
when the trimer is not yet fully opened36.
This capacity of bnDs is likely favored by their small molecular
size. Indeed, Fab fragments of the probed V3 crown mAbs gained
neutralizing potency in the absence of V1V2 to a similar extent as
bnDs (ranging from 68- to 459-fold, Supplementary Fig. 8a, b,
Supplementary Data 4). Overall, Fabs showed higher potency
against V1V2-deleted viruses compared to bnDs but lacked in
activity against wild-type viruses, where bnD.2 and bnD.3
reached higher breadth (Supplementary Fig. 8c). Together this
suggests that a particular capacity to bypass V1V2 shielding,
rather than binding affinity, shapes the neutralization capacity
of bnDs.
Due to their rigid interaction surface, DARPins often bind to a
specific conformation of their target, as exemplified by the cross-
neutralizing V3 DARPin 5m3_D1226,27,31. We thus examined the
structural preferences of the V3-crown bnDs by comparing their
reactivity with a linear V3-crown peptide and four structurally
constrained V3-crown mimetic peptides. The V3-crown mimetic
peptides (named V3-IY, V3-IF, V3-RY, V3-RF according to
residues forming inter-strand hydrogen bonds) were designed to
match distinct β-hairpin conformations of the V3-crown that had
previously been identified in complexes with V3-crown
mAbs23,27,37–40 (Supplementary Fig. 3a, b). Unlike DARPin
5m3_D12, all three bnDs reacted well with diverse V3 peptides
immobilized to a solid phase, including V3 mimetics and linear
V3 (based on sequences from the reference clade A strain BG505
and the clade B strain MN) (Supplementary Fig. 3c and
Supplementary Data 3). Overall, bnD.3 displayed the strongest
binding to the diverse V3-crown peptide variants. Competition
binding in solution revealed, however, distinct conformational
preferences (Fig. 2b and Supplementary Fig. 3d). For the bnDs,
the strongest competition was generally observed with a
structurally defined V3-crown mimetic, which outperformed
linear V3-crown peptides in all comparisons. From these
observations, we conclude that the structure of the V3 has a
contributing role in bnD binding. For bnD.1 and bnD.2, the
BG505 Competitor Related structure
V3 none (linear)
V3-IY F425-B4e8 Ab-bound V3
V3-IF 2219 Ab-bound V3
V3-RF 537-10D Ab-bound V3
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Fig. 2 V3 DARPins depend on CD4 triggering to bind native HIV-1 Env. a Binding of biotinylated DARPins to cells expressing Env (JR-FL) was assessed by
flow cytometry. Histograms of normalized fluorescence intensities and corresponding plots showing mean fluorescence intensities (MFI) as a function of
concentration are depicted. Top: DARPin (0.5 µM) binding in the presence of increasing concentrations of sCD4. Bottom: DARPin binding at increasing
concentrations in the presence of 2 µM sCD4. Background binding was assessed on cells expressing Mulv Env (shown are representative MFI data for the
three bnDs). b Competition ELISA to probe for V3-crown conformational preferences of DARPins. DARPin binding to immobilized recombinant Env-derived
proteins was measured at a concentration just before reaching saturation. Env proteins were chosen to maximize the dynamic binding range for the
individual DARPin (bnD1: BG505gp120ΔV1V2; bnD.2: JR-FLgp120; bnD.3: trimeric BG505-SOSIP). Each DARPin/Env pair was competed with increasing
concentrations of the BG505 V3 peptides indicated in the legend.
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strongest competition was observed for mimetic V3-IF, and
bnD.3 favored V3-RY, V3-IY, and V3-IF.
Crystal structures of the V3-crown DARPin: epitope complexes
reveal two distinct V3 conformations linked to broad neu-
tralization. In order to define V3-crown epitopes that lead to broad
neutralization, we co-crystallized bnDs with V3-IF (BG505), i.e., the
V3-crown mimetic that all bnDs bound best (Fig. 3, Supplementary
Fig. 9 and Supplementary Data 5). 5m3_D12 and 63_B7 were co-
crystallized with V3-IY (MN). Since 63_B7 also bound well to the
linear peptide, it was additionally crystallized in complex with linear
V3-crown peptide (MN). The canonical DARPin structure with the
adjacent ankyrin repeats was maintained in all analyzed complexes
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As expected from the pronounced preference of 5m3_D12 for
V3-IY register mimetics (Supplementary Fig. 3c27), the structure
of the isolated V3-IY mimetic was also retained in complex with
5m3_D12 (Fig. 3a and Supplementary Fig. 9a). In contrast, V3-IY
and V3-IF mimetics in complex with the three bnDs and 63_B7
adopted conformations that were different from their original
design (Supplementary Fig. 3a, b). In all cases, a loss of the
mimetic’s β-hairpin conformation was observed (Fig. 3a). Two
distinct V3-crown conformations emerged, each captured by two
different DARPins (Fig. 3a, Supplementary Fig. 9e, g). The V3
conformation adopted in complex with bnD.1 and bnD.3 proved
highly similar to the structure of linear V3 peptide bound by mAb
3074 (5, PDB ID: 3mlx, Fig. 3a and Supplementary Fig. 9g). In
contrast, V3-IF in complex with 63_B7 and bnD.2 adopted a
conformation strongly resembling the cryo-EM structure of the
V3-loop on gp120 when bound to co-receptor CCR5 (2, PDB ID:
6meo) which features a helical turn in the C-terminal strand
(Fig. 3a, b and Supplementary Fig. 9e). Considering this
similarity, the conformation of V3 bound to bnD.2 will herein-
after be referred to as Post-CCR5-V3. Since bnD.1 and bnD.3 also
target the V3 post-CD4 engagement, the conformation adopted
by V3 in complex with these DARPins must either be a transitory
intermediate state that occurs prior to CCR5 binding or an
induced fit upon binding an intermediate. This conformation will
hereinafter be referred to as Inter-CCR5-V3.
The V3-crown conformational space was investigated by
performing a molecular dynamics (MD) simulation of fully
glycosylated gp120 bound by CD4 (based on the CD4 and CCR5
bound gp120 PDB ID: 6meo2). A principal component analysis
(PCA) of the conformations sampled by the V3-crown was then
carried out. The V3-crown structures determined in complexes
with DARPins or antibodies were projected into the eigenspace
defined by the first two principal components (Fig. 3c). MD
simulation suggested a high conformational flexibility of the V3
loop with β-hairpin variants being adopted most frequently and
covering all experimentally determined V3 structures. Note-
worthy, we observed that the Post-CCR5-V3 conformation is
occasionally sampled spontaneously, possibly promoting the
interaction with either CCR5 or bnD.2 (Fig. 3b). In contrast,
the Inter-CCR5-V3 conformation was sampled less often in the
MD simulations, suggesting that bnD.1 and bnD.3 must have the
means to efficiently interact with V3 prior to the adoption of this
V3 state.
The capacity of the bnDs to induce a fit or capture a transient
conformation (conformational selection) was supported by
additional observations. MD simulations showed that the
conformational space of the V3-crown mimetics and the linear
V3-crown peptide is strongly reduced when compared to the V3
loop on gp120 (Supplementary Fig. 10d–h). This is in agreement
with Nuclear Magnetic Resonance (NMR) data of the V3-crown
mimetics27 and confirms that mimetics only rarely adopt the
Post-CCR5-V3 conformation. Despite this observation, the
different V3-crown mimetics, as well as linear V3-crown peptide,
were able to adopt the Post-CCR5-V3 conformation when in
complex with 63_B7 and bnD.2 (Fig. 3b and Supplementary
Fig. 9c, e). It should be noted that 63_B7 and bnD.2 were selected
using different panning targets (V3-IY mimetic and CD4-bound
gp120, respectively), thus highlighting again that a common
transient conformation of the V3 must exist.
bnDs engage conserved residues in the V3-crown. The analysis
of the buried surface area (BSA) of the V3-crown mimetics across
DARPin-complexes revealed several important features in the
interaction motifs (Fig. 3d and Supplementary Data 6). Despite
different preferences for the Inter- or Post-CCR5-V3 conforma-
tion, the bnDs overlapped in their contact patterns, engaging
mainly with R/H308, I309, P313, F317, and Y318. All these
residues are highly conserved across HIV-1 strains (>79%) except
for position 308 where both arginine (42%) and histidine (31%)
are frequently present (Supplementary Fig. 6a). The R308 side
chain engages via a salt bridge with bnD.1 and bnD.2 (Fig. 3d,
Supplementary Fig. 9f, h). Despite this contact, the bnDs main-
tained neutralization capacity against viruses with different resi-
dues in position 308 (Supplementary Data 1, Supplementary
Figs. 5 and 6b), indicating the energetic importance of the other
interactions. 63_B7 was the only DARPin that made substantial
contact with the side chain of R315, which is prevalent only in
clade B strains41. This would explain the restriction of 63_B7 for
this clade (Supplementary Data 1). H-bonds formed with V3-
crown peptide side chains and backbone differed substantially
across DARPins (Fig. 3d and Supplementary Fig. 9). However, a
striking commonality found across all DARPins was H-bonding
with Y318.
Overall, we observed that bnD.3 forms eight H-bonds,
distributed across six V3 amino acid residues, thus potentially
leading to the comparatively high binding affinity observed for
this DARPin (Supplementary Fig. 3c, and Supplementary Data 3
and 4). Six of these bonds were established with the V3-crown
peptide backbone, and as a result, this should make bnD.3 less
sensitive to V3 sequence variations. These features probably
contribute collectively to the observed higher neutralization
breadth of bnD.3 compared to bnD.1, which covers a BSA similar
to bnD.3, but only forms four H-bonds with V3. In addition to
Fig. 3 V3-crown conformations recognized by bnDs and binding modes. a Comparison of V3 conformations in complex with DARPins, mAbs, the CCR5
co-receptor, and in the partially open (b12-bound) Env trimer. 5m3_D12 and 63_B7 were co-crystallized with V3-IY (MN). bnD.1, bnD.2, and bnD.3 were
co-crystallized with V3-IF (BG505). b Structural alignment of V3-IF (plum) in complex with bnD.2 (green) and CCR5-bound V3 (ice blue) (PDB ID: 6meo).
For clarity, the D-Pro-L-Pro template of the V3-IF mimetic was omitted from the representation. c Principal component analysis for the conformational
space sampled by the unliganded V3-crown during a molecular dynamics simulation of sCD4-bound, glycosylated gp120 initiated from the CD4 and CCR5-
bound conformation (PDB ID: 6meo). Contour levels depict the frequency of adopted V3 conformations. The position of experimentally determined
liganded V3 structures in the conformational space are marked by a diamond (V3-crown DARPin), Y (V3 mAb), or X (CCR5 co-receptor or CD4-binding
site mAb b12) and labeled with the name of the respective ligand. Coloring according to a. d Summary of DARPin:V3-crown peptide interactions observed
in the crystal structures listing the distribution of the buried surface area (BSA) on V3, total BSA, H-bonds (H), and salt-bridges (S). (Hb) indicates
H-bonds with the V3 peptide backbone. The positional amino acid frequency (PAF) indicates how often each amino acid in the V3 peptide occurs in HIV-1
strains across group M (the V3 consensus sequence of group M is identical to V3 of strain BG505) (Supplementary Fig. 5). e Visualization of the
interaction interface of bnD.2 (green) and bnD.3 (cyan) by structural alignment of the V3 peptides in PyMol. The side chains of key contact residues on V3
used by both bnDs are depicted with sticks. f Binding of V3-directed bnDs and mAbs modeled on the open Env trimer structure (bound by CD4 and the co-
receptor-mimicking mAb 17b, PDB ID: 5vn311. Surface representation of gp41 (dark grey), gp120 (light grey), CD4 (purple), bnD.2 (green) and bnD.3
(cyan). The approach angles of the mAbs were computed by principal component analysis based on the structural coordinates of each Fab-fragment and
are indicated with orange rods.
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the hydrogen bonds, additional hydrophobic contacts add to the
interaction strength (Supplementary Fig. 9b, d, f, h, i).
bnDs approach the V3-crown loop from opposite sides. The
bnDs make extensive contacts with Y318 and F317 which are
exposed to opposite sides of the V3 loop in the Inter- and Post-
CCR5-V3 conformations, due to the presence or absence of the
helical turn. This enables bnD.2 to approach the V3-crown from
the opposite side compared to bnD.1 and bnD.3, and to interact
with several shared conserved contact residues on the V3-crown
(Fig. 3d and e).
In order to compare the relative orientations of the bnDs, Abs
and Env, we carried out docking experiments incorporating the
structural flexibility of the V3 loop sampled by the MD
simulation of the glycosylated gp120 bound to CD4 (Fig. 3f and
Supplementary Fig. 11). The bnD.3/bnD.1/3074 epitope is
exposed to the outside of the trimer with mAb 3074 approaching
the trimer from the top similar to DH753. In contrast, the
epitopes of mAbs 2219 and F425-B4e8 face the two neighboring
protomers. This allows only for a shallow approach angle of the
Abs which, nevertheless, allows access for notable neutralization
activity (Fig. 1c, d and Supplementary Fig. 8c). This provides
further support for the accessibility of the bnD.2 epitope on
functional Env, as bnD.2 binds the V3 from the same side as V3-
crown Ab 2219 (and 447-52D)5,19,25.
Functional mapping of the V3 DARPin epitopes. To probe the
functional relevance of individual amino acids for neutralization
by the V3-crown DARPins, we conducted an Env mutational
scanning analysis encompassing 130 point mutants within gp120
(Fig. 4, Supplementary Data 7). V3-crown mAb 447-52D was
included for comparison. A range of Env single-residue mutants
showed enhanced neutralization sensitivity to V3-crown directed
agents, indicating a more open Env trimer structure with
increased V3 exposure (e.g., I309A, F317A, Y318A, Q422A, and
K432A, see Fig. 4a and Supplementary Data 7). Notably, mAb
447-52D benefited from improved access to a much higher extent
than the bnDs, reminiscent of the effect of V1V2 deletion (Sup-
plementary Fig. 8b) suggesting that antibody access may have a
greater dependence on complete trimer opening than bnDs.
Resistance mutations, defined by a > 5-fold increase in IC50 of
mutant over wild-type virus, were mapped onto the crystal-
structure of gp120 complexed with CD4 and CCR52 (Fig. 4b–e).
Despite shared contact residues (Fig. 3d), identified resistance
mutations showed comparatively little overlap across DARPins.
Only Y318 proved to be critical for most DARPins, but also for
this residue influence varied depending on the Env context
(Fig. 4a).
Five shared resistance mutations highlighted the similarity
between bnD.2 and 63_B7 (Fig. 4a and Supplementary Data 7).
These positions (T257, K282, P470, M475, W479) localize outside
V3 near the interface of the gp120 inner and outer domains and
involve residues of the CD4 binding site and/or layer 3, a
structural element previously implicated in Env conformational
transitions42. Mutation of the neighboring residues N280 and
D474 also showed an effect on bnD.2 and 63_B7, although the
5-fold threshold was not reached in both cases. The P470A
mutation also influenced bnD.3 potency but stayed below the
5-fold threshold for bnD.1.
The removal of glycosylation sites surrounding the V3 loop
(N197, N332, N386) had hardly any effect on bnD activity
(Fig. 4a and Supplementary Data 7). Observed decreases in
sensitivity were less than 5-fold. Removal of N332 led to higher
sensitivity to all three bnDs but the increase was less than 5-fold.
We only noted a potential effect of glycosylation on 5m3_D12:
Introduction of a glycan at N197 strongly decreased sensitivity,
conversely the T388A substitution (and to a lower extent also
N386A) led to a decrease in sensitivity, suggesting that loss of this
glycan may lead to altered structural dynamics of the V3 loop that
do not favor 5m3_D12 binding. In support of this, the V3-IY
conformation preferred by 5m3_D12 was only rarely sampled in
a V3 MD simulation on deglycosylated gp120 (Supplementary
Fig. 10).
Accessibility of V3-crown bnD epitopes. Due to their smaller
size, DARPins (~16 to 20 kDa, depending on the number of
ankyrin repeats, see Supplementary Fig. 4) may access restricted
sites more easily than Abs (~150 kDa). In order to assess the
influence of space constraints, we generated bivalent Fc fusion
proteins of each bnD (Fig. 5a; bnD.2-Fc: ~80 kD; bnD.1-Fc and
bnD.3-Fc: ~85 kD). Like the monovalent DARPins, bnD-Fcs
required CD4 triggering to bind cell surface-expressed JR-FL Env
(Fig. 5b) while V3-crown mAbs display a low-level binding also
in the absence of CD4 at equivalent concentrations (Supple-
mentary Fig. 12). We next compared bnD-Fc binding to a
recombinant native-like Env trimer, BG505-SOSIP8,43,44, which is
known to partially expose V344 (Fig. 5c, Supplementary Data 9).
The effect of bivalency on binding V3 on BG505-SOSIP varied
considerably across bnDs. While the binding for the bnD.3-Fc
improved substantially, bnD.1-Fc binding activity remained
unchanged and bnD.2-Fc even recorded a strong loss in binding
capacity. Binding to trimeric BG505-SOSIP lacking V1V2
improved for bnD.1-Fc and to a lesser extent for bnD.2-Fc over
the monovalent DARPin version, while bnD.3-Fc gained less in
activity compared to binding to the wt protein (Fig. 5c, Supple-
mentary Data 9). Collectively, this suggests that bnD.1 epitopes
are arranged such that a bivalent engagement across the trimer is
not possible, and that the bnD.2 epitopes are not accessible for the
larger sized bnD.2-Fc in its current design. Neutralization effi-
ciency of the bnD-Fcs against wt and V1V2-deleted viruses
revealed a similar pattern (Fig. 5d, Supplementary Fig. 13, and
Supplementary Data 9). Unlike bnD.2-Fc, bnD.1-Fc showed a
moderate, bnD.3-Fc a stronger consistent increase in potency
compared to their monovalent counterparts against V1V2-
deleted viruses and the neutralization sensitive (Tier-1) strain
SF162. Remarkably, when probing neutralization of difficult-to-
neutralize (Tier-2) wt viruses, bnD.3-Fc fully retained its activity
while bnD.1-Fc and bnD.2-Fc showed less activity than their
monovalent counterparts. Interestingly, bivalent V3-crown mAbs
had a modestly higher potency against wild-type Env compared
to their monovalent Fab version while bivalent binding strongly
improved potency against V1V2-deleted Env (Fig. 5d). Thus,
although wild-type Env not only restricts access to the V3 but also
bivalent binding, full-sized V3-crown Abs performed on average
better than corresponding Fab molecules.
Collectively this indicates that both for V3-crown Abs and
bnDs the exposure of the epitope during the entry process rather
than the size of the inhibitor regulates neutralization efficacy. The
analysis of bivalent bnD-Fc binding and neutralization activity
highlights the overlapping influences of avidity gain and steric
constraints. The observed differences amongst the three bnD-Fcs
are in agreement with our docking studies which placed the
bnD.1/bnD.3 epitopes to the outside of the trimer and thus more
accessible than the bnD.2 epitope located between two protomers.
Further space constraints for bnD.2-Fc may result from the
C-terminal linked Fc facing the host-cell membrane (Fig. 3e and
f). These constraints may in part be specific to the design of the
bnD.2-Fc construct, as the bnD.2 epitope is accessible for larger
sized inhibitors such as mAb 10A37 (Fig. 5d and Supplementary
Fig. 8c) which recognizes a similar V3 conformation than
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27075-0 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6705 | https://doi.org/10.1038/s41467-021-27075-0 | www.nature.com/naturecommunications 7
bnD.245,46, and mAb 2219 which approaches V3 from a similar
angle (Fig. 3f). Of particular note, even as an 85-kD Fc fusion
protein, bnD.3 showed sustained neutralizing potency, under-
lining that the V3-crown can be effectively targeted by larger
agents.
Distinct patterns of V3-crown plasma antibody reactivity are
linked with neutralization breadth. We next investigated whe-
ther naturally occurring V3-crown Abs exist that share with bnDs
a preference for distinct V3-crown conformations. Probing a
range of V3-crown mAbs we found that most, but not all, bind
better to the linear V3-crown peptide than the four V3-crown
mimetics (Supplementary Fig. 14a). Reactivity of the mAbs
towards the mimetics differed, with most mAbs binding the V3-
crown mimetics V3-IY and/or V3-IF better than V3-RF and V3-
RY, further illustrating conformational preferences. Only mAb
2442 bound all mimetics with similar affinity.
We next leveraged the well-characterized patient cohort of the
Swiss 4.5 K Screen13,47 to assess a potential impact of V3






























Env-mutant region feature 5m3_D12 SE4 SB11 63_B7 bnD.1 bnD.2 bnD.3 447-52D
V120A C1 - BrS 12.0 2.8 1.0 0.5 2.6 1.7 1.7 0.9
D197N (§) C2 PNGS 77.8 0.6 1.0 1.3 1.4 3.8 1.9 4.2
T257A C2 2.4 1.4 1.0 9.0 2.2 5.0 2.7 0.6
N280A C2 CD4-bs 0.3 0.5 1.0 3.4 1.6 5.5 1.1 1.7
K282A C2 CD4-bs 3.2 1.4 0.7 5.8 1.6 5.2 1.5 1.3
T283A C2 CD4-bs 0.4 0.3 0.6 0.4 2.1 5.5 1.2 1.2
I309A V3 8.6 0.01 0.0017 0.4 0.2 7.1 1.3 0.0008
P313A V3 63.3 0.11 0.4 9.0 0.6 2.8 6.3 4.2
R315A V3 0.9 0.4 0.3 9.0 1.3 0.4 1.6 4.2
F317A V3 3.2 5.8 0.01 0.17 0.2 4.3 23.4 0.0006
Y318A V3 63.3 27.0 0.0053 9.0 0.7 27.4 19.0 0.0010
Y318A (*) V3 nd nd nd nd 111.2 17.2 23.3 nd
G321A V3 3.0 25.1 0.7 0.6 1.8 0.8 0.9 0.5
E322A V3 0.6 16.8 0.9 1.7 1.1 1.1 1.0 3.9
N332A V4 PNGS 1.7 0.20 0.18 0.2 0.3 0.3 0.3 0.09
N386A V4 PNGS 3.1 1.2 1.0 1.1 0.9 4.1 0.9 0.4
S387A V4 3.6 0.9 1.0 2.0 2.4 1.1 0.6 1.8
T388A V4 PNGS 21.2 2.6 1.0 1.3 1.8 4.6 2.1 0.5
Q422A C4 - BrS 0.2 6.1 0.4 0.16 0.10 0.8 0.13 0.0012
K432A C4 - BrS CD4-bs 41.7 0.4 0.7 0.8 0.14 2.0 0.6 0.0023
I467A C5 1.5 0.7 1.0 1.1 0.9 6.2 1.0 0.8
P470A C5 0.9 2.0 1.0 9.0 3.0 7.5 6.4 0.11
D474A C5 - layer 3 CD4-bs 0.8 1.0 1.0 5.6 1.0 4.1 0.9 1.0
M475A C5 - layer 3 CD4-bs 4.9 1.3 1.0 9.0 2.1 8.3 2.6 3.0
W479A C5 - layer 3 3.4 0.9 1.0 9.0 3.6 10.1 2.6 0.01
DARPin resistance mutations (IC50 ratio mut/wt)
Fig. 4 Mutational scanning reveals key residues that determine sensitivity to V3 bnDs. Mutational scanning of gp120 was performed across a 130 Env-
pseudovirus mutant panel (Supplementary Data 7 and 8). a Overview of Env mutants that lead to >5-fold increase in IC50 compared to wt Env for at least
one DARPin. For the DARPins, IC50 values for each mutant represent geometric means from at least two independent experiments (Supplementary
Data 8). IC50 ratios (IC50mutant/IC50wt) are depicted. Light orange 5 < IC50-ratio<10; orange IC50-ratio>10; light grey 0.01 < IC50-ratio<0.2; dark grey
IC50-ratio<0.01. PNGS: potential N-glycosylation site; CD4-bs: CD4-binding site; BrS: bridging sheet; C1-C5: Env constant regions 1-5; V1-V5: Env variable
regions 1-5. b-e Structure of gp120 as in complex with sCD4 and CCR5 (PDB ID: 6meo; gp120 inner domain (dark grey), gp120 outer domain (light grey),
V1V2 base (cyan), V3-base (dark blue), V3-stem (green), V3-crown (orange). Amino acid substitutions leading to a > 5-fold increase in the respective
DARPin IC50 compared to the wt Env are indicated in red. (*/§): Mutations with >5-fold increase in IC50 identified in different Envs: BG505 (*) or JR-FL (§).
JR-FL naturally lacks the glycosylation site at position 197.
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Fig. 5 Activity of bnDs as bivalent molecules. aModel of a bivalent DARPin-Fc generated by fusing the DARPin (violet with orange interaction surface) to
the N-terminus of the Fc-region of human IgG1 (light grey and dark grey for the paired chains) with a preserved hinge region. b Binding of bivalent DARPin-
Fc fusions to cell surface-expressed Env (JR-FL) measured by flow cytometry. DARPins-Fc fusions were titrated and incubated with cells in the presence or
absence of 2 µM sCD4. Mulv Env served as a negative control. Histograms of normalized fluorescence intensities (top panel) and dose-response curves
with mean fluorescence intensities (MFI, bottom panel) are depicted. See also linked experiments in Supplementary Fig. 12. c Binding of increasing
concentrations of monovalent DARPins and bivalent DARPin-Fc fusions to wt (BG505-SOSIP) and V1V2 deleted Env trimer (BG505-SOSIPΔV1V2) in
ELISA. Representative relative luminescent unit (RLU) data from one of two independent experiments are shown. d Comparison of monovalent and bivalent
V3 inhibitors. Log IC50 ratios (Fabs/mAbs and bnDs/Fc-bnDs) from a panel of 9 Tier-2 viruses (top) and corresponding V1V2-deleted viruses (bottom) are
depicted. Values > 1 indicate higher potency of the bivalent inhibitor version. Individual data points are shown as circles and were calculated from
geometric means of two independent experiments for wt and V1V2-deleted virus respectively (n= 2). Pairs with resistant strains were not included in the
plots. Box plot limits extend from the 25th to 75th percentiles; centerline: median; whiskers indicate the minimum and maximum values. See
Supplementary Data 9 and Supplementary Fig. 13 for a full data set.
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individuals with chronic HIV-1 infection for whom detailed
information on plasma neutralization activity, anti-HIV binding
Abs, patient demographics, and disease parameters have been
established13,47. First, we compared the binding reactivity of
plasma IgG1 to linear V3-crown peptide (strain BG505) and the
four corresponding V3 mimetics (V3-IY, V3-IF, V3-RY, and V3-
RF) across the cohort (Fig. 6 and Supplementary Fig. 14b).
Correlation analysis showed that the relative V3-crown binding
activities formed two reactivity clusters, one comprising the linear
V3-crown peptide together with V3-IY and V3-IF and the other
comprising V3-RY and V3-RF (Fig. 6a), underscoring that V3-
crown antibodies with different conformational binding prefer-
ences occur in HIV-1 infection.
Two-dimensional V3 response maps based on the dimension-
ality reduction algorithm t-SNE showed distinct areas with high
V3 reactivity that overlapped between V3 probes (Fig. 6b).
Visualization of V3 patterns in sub-groups based on neutraliza-
tion activity revealed no distinct clustering (Supplementary
Fig. 15). Cross, broad, or elite plasma neutralization capacity
and top 105 neutralizers stratified according to their predicted
bnAb specificity as defined in47 showed overall no strong
accumulation in V3 dense areas of the t-SNE plots. A degree of
clustering was however evident amongst certain bnAb specificities
amongst top neutralizers, in particular for trimer-apex predicted
plasmas (Supplementary Fig. 15b). As we previously observed
that trimer-apex (V2) responses are more prevalent outside
subtype B47 and these plasma should react better with the subtype
A (BG505) based antigens in binding, this accumulation in the
t-SNE plots has to be expected and alone cannot define an
association between bnAb activity and V3 binding responses.
To control for influences of co-variables we next conducted a
multivariable linear regression analysis analyzing the influence of
patient and disease parameters on relative binding activities to V3
probes (linear V3 and mimetics) and Env targets (gp120 and
trimer) (Supplementary Fig. 14c). Previous analyses of the Swiss
4.5 K Screen identified an influence of infection length, viral load,
virus diversity, and black ethnicity on the development of
neutralization breadth and IgG responses to HIV-1 Env
antigens13,47. Here, we found that length of untreated infection
and transmission by injection drug use (which entails prolonged
periods of untreated HIV-1 infection), correlate positively with





















































0.76 0.72 0.66 0.79 1.00
0.85 0.73 0.71 1.00 0.79
0.88 0.89 1.00 0.71 0.66
0.89 1.00 0.89 0.73 0.72
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Fig. 6 The V3-crown IgG1 response in HIV-1 infection recognizes distinct V3-crown conformations and is linked with the development of
neutralization breadth. Relative plasma IgG1 binding activity (distributed uniformly in [0,1]) to linear V3 and structurally constrained BG505 V3-crown
mimetics (V3-IY, V3-IF, V3-RF, V3-RY) from 4281 chronic HIV-1 infected individuals enrolled in the Swiss 4.5 K Screen13, 47 were obtained and assessed in
the context of neutralization activity data of the cohort (defined as a cross, broad and elite neutralization, or no neutralization) available from47. Source
data are provided as Supplementary Data 10. a Unweighted average linkage hierarchical clustering based on the Spearman correlation of relative V3-crown
peptide IgG1 binding activities across the cohort indicates reactivity clusters dependent on V3-crown peptide conformation. b A two-dimensional
representation (t-SNE map) of all 4,281 plasma samples based on relative IgG1 binding activities to the five V3 peptides. Red color denotes high binding
activity and blue color denotes low binding activity to the V3 peptide indicated on the top of each panel. c Comparison of relative V3 binding activity in
plasma from patients with (n= 909) and without (n= 2250) heterologous virus-neutralizing activity by multivariable linear regression analysis. Grey bars
indicate the mean difference in relative binding activity for individual peptides (two-tailed p-values from t-test are provided; they are not adjusted for
multiple testing). Black error bars indicate the 95% confidence intervals. These data belong to a comprehensive analysis of host, virus, and disease
parameters, shown in Supplementary Fig. 14c and Supplementary Data 11, where only the n= 3159 patients with complete information on all parameters
were included. d The top 105 neutralizing plasmas of the cohort were stratified by bnAb epitope specificity (using neutralization fingerprinting47) and their
mean relative V3 binding activities were compared.
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(Supplementary Fig. 14c). Viral load, which correlated strongly
with trimer and gp120 IgG1 responses was not associated with
increased V3 antibody responses, highlighting epitope-specific
differences in the parameters that steer binding antibody
responses, as also noted by Kadelka et al.13. As noted before,
the reactivity of plasma with the Env antigens proved to be
subtype-dependent, with subtype B plasmas showing higher
reactivity with subtype B derived antigens (MN and JR-FL) and
non-subtype B plasmas showing higher reactivity with BG505
antigens. Likewise, we confirmed black ethnicity as a driver of
IgG1 binding responses including V3 responses (Supplementary
Fig. 14c and Kadelka et al.13). Most intriguingly, when comparing
Swiss 4.5 K patients with and without neutralizing activity by
multivariable linear regression, we found that neutralizing plasma
activity was associated with higher IgG1 binding activity for V3-
crown peptides, with the strongest association observed for
reactivity with the V3-IY mimetic (Fig. 6c).
This higher prevalence of V3-crown-specific antibody
responses among broad neutralizers is intriguing and suggests
that V3 responses are influenced by the same disease parameters
as bnAbs, but may evolve independently and can serve as
surrogate markers for the evolution of bnAbs. Alternatively, V3-
crown responses may be functionally linked to the evolution of
bnAbs. For example, escape of V3-crown Abs may drive the
evolution of different bnAb types. In addition, rare V3-crown
mAbs may themselves exhibit notable neutralizing breadth.
To gain further insight into the potential functionality of V3-
crown responses, we next examined whether V3 reactivity was
uniformly high among bnAb inducers or whether differences
existed depending on the bnAb specificity elicited again utilizing
the top neutralizers with predicted bnAb specificity (Fig. 6d).
Intriguingly, we found that V3 reactivity differed depending on
the bnAb specificity of the plasma with CD4bs bnAb predicted
plasma recording the highest V3 reactivity. V3-glycan bnAb
reactivity was associated likewise with high V3 peptide reactivity
across all probes, whereas V2-glycan bnAb plasmas showed high,
but differential reactivity across V3 probes. Plasmas with yet
unidentified bnAb specificity and MPER bnAb predicted plasmas
showed lower V3 reactivity than the other bnAb plasmas but also
for these plasmas the reactivity was higher than in non-
neutralizers in agreement with the analysis in Fig. 6c.
In conclusion, the population-wide survey of V3-crown
responses in the Swiss 4.5 K cohort (n= 4281) lends support to
the idea that the naturally occurring antibody response in HIV-1
infection is shaped to distinguish conformational differences of
V3 (Fig. 6a). The V3-crown response appears to co-evolve with
neutralization breadth (Fig. 6c and d), highlighting the impor-
tance of deciphering which V3 responses are an irrelevant by-
product and which are a direct or indirect component of bnAb
evolution.
Discussion
Harnessing the potential of the V3-crown for HIV-1 inhibition
has been attempted for several decades. Termed initially the
principal neutralization domain, it rapidly became evident that
V3-crown neutralization by antibodies is rendered inefficient due
to its conformational masking9,48. Moreover, the immunodomi-
nance of the V3-crown is thought to distract the antibody
response from known bnAb epitopes by competition for T folli-
cular helper cells during affinity maturation in germinal centers49.
For these reasons current Env-immunogen design seeks to avert
the immunodominant V3-crown response as exemplified by the
new generations of well-shielded, stabilized, soluble Env trimer
immunogens50–54. Nonetheless, exploiting the V3-crown remains
a tempting target because of its functional importance, sequence
conservation, and high immunogenicity — potentially all key
factors for efficient inhibition. V3-crown antibodies show
exceptional potency and cross-reactivity in the absence of V1V2-
shielding9. Thus, the potential for effective inhibition is present,
provided shielding can be bypassed.
In this study, we demonstrate that broad neutralization,
reaching up to 90% of breadth, via the V3-crown can indeed be
achieved by creating novel DARPin-based inhibitors. The large
breadth of the V3-crown bnDs is even more astonishing as they
are currently still substantially less potent than bnAbs targeting
prefusion Env. The discovery of the bnDs provides proof that the
V3-crown, although only transiently exposed on the open Env
during viral entry, is widely targetable across divergent strains.
The bnDs further define two conformations, Inter-CCR5-V3 and
Post-CCR5-V3 that expose conserved residues and are accessible
on the CD4-triggered Env trimer.
MD simulations suggest that the V3-crown samples various
conformations before CCR5 engagement. Molecular docking
suggests that the Inter-CCR5-V3 conformation, defined by bnD.1
and bnD.3, may thereby be exposed already on a partially open
trimeric Env11 (Supplementary Fig. 11b). bnD.2 cannot access V3
on this Env conformation due to steric hindrance by V1V2. This
bnD requires CD4-triggered Env with a more exposed V3 to bind.
The capacity of bnD.2 to bind Env similarly to CCR5 in the Post-
CCR5-V3 conformation may, however, be a key component of its
extraordinary neutralization breadth. All three bnDs benefit less
from V1V2 deletion than nAbs, supporting the notion that bnDs
can access a comparatively early - partially - opened state of the
trimer36. This notion is further strengthened by the fact that bnD
potency does not benefit from point mutations opening the tri-
mer to the same extent compared to V3 mAb 447-52D, for which
we noted strongly enhanced neutralization potency. While V3-
crown mAbs in part also access partially open Env, space con-
straints appear to restrict bivalent binding unless V1V2 shielding
is completely released. Overall, this indicates that access is less of
a limiting factor for neutralization by V3-binding bnDs than V3
antibodies, with the latter likely requiring complete and pro-
longed opening of Env to be fully effective.
The majority of bnAbs function by neutralizing free virus36,55.
A notable exception is a group of bnAbs targeting the membrane-
proximal-external-region (MPER) on gp41 that are known to
require CD4 triggering to efficiently bind Env56,57. MPER bnAbs,
like V3-crown bnDs, are remarkably broad, but not very potent58.
Other bnAbs also exhibit post-CD4 activity, as demonstrated
during cell-to-cell transmission, where likewise a broad but not
very potent activity is seen59,60. The overall lower potency of
post-CD4 neutralizing activity is with great certainty a con-
sequence of the transient and brief exposure of these Env states.
This makes the activity of V3 bnDs all the more remarkable.
Intriguingly, bnAb VRC01 which failed to protect against HIV
acquisition in the AMP trial61 has high potency against the free
virus but not post attachment and during cell-cell
transmission59,60. Combining bnAbs with high potency against
the free virus with inhibitors that provide inhibition after binding
to CD4, such as the novel V3-crown bnDs described here, would
increase the options for effective entry inhibition and is worth
exploring in forthcoming studies. Therapeutic development of
DARPins has been demonstrated in other disease models26,62–65.
DARPins are being evaluated in late-stage clinical trials for, e.g.,
COVID (ensovibep62,66), cancer (MP031067), or neovascular age-
related macular degeneration (abicipar68). DARPins can be
refined by a large variety of engineering strategies increasing
valency, potency, and half-life26,69–79,(and Supplementary Fig. 1).
CD4 triggering occurs gradually as demonstrated by a step-
wise exposure of neutralization sensitive epitopes36. Access of the
V3-crown bnDs to early opening Env intermediates, as our results
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suggest, maybe decisive for their activity, as it elongates their
window of opportunity. Certain post-receptor engagement con-
formations may also be sampled by Env spontaneously and might
be trapped by the bnDs19,80. We observed no exposure of the bnD
epitopes in the absence of CD4 in our experimental setup using a
relatively neutralization-resistant Env (Tier-2 strain JR -FL).
However, spontaneous conformational sampling may differ
among strains and needs to be taken into consideration19,36,81.
Collectively, these observations demonstrate that post-CD4 con-
formations of Env may be more widely accessible for neu-
tralization before and during the entry process than was
previously thought and could be exploited. The description of
inhibitor-targetable V3-crown conformations defined here is,
therefore, an important step in this direction.
Although bnDs benefit from their smaller size in accessing the
distinct V3 conformations post-CD4 engagement, the analysis of
bivalent Fc-fusion constructs together with mAb-Fab-pairs
highlights that larger molecules can also access these regions.
Spatial constraints inflicted by the V1V2, host cell membrane,
and neighboring Env protomers however differentially affect
access to epitopes depending on the size and epitope of the
inhibitors. As demonstrated by bnD.3, high affinity and avidity
effects can counterbalance the access limitations of larger mole-
cules. Therefore, antibodies could also benefit from these effects
to attack this domain efficiently.
In this study, we linked strong V3-crown responses with
neutralization breadth in chronic HIV-1 infection (Fig. 6b, c).
Whether these binding reactivities are a surrogate response that
evolves alongside bnAbs without having a direct effect, whether
they are indicative of the evolution of rare V3-crown bnAbs, or
whether they resemble a contribution of V3-crown Abs as helper
lineages for other bnAbs, remains to be defined. A proof of
principle that the V3 conformations recognized by the bnDs are
also targetable by antibodies comes from structure analysis of two
V3-crown mAbs that neutralize some Tier-2 viruses but lack
overall breadth. MAb 10A37 targets a conformation closely
related to Post-CCR5-V3 bound by bnD.245,46. MAb 3074
recognizes a conformation of V3 similar to Inter-CCR5-V3
recognized by bnD.1 and bnD.3 and approaches V3 from the
same side as these DARPins5,19,20,82. mAb 3074-like Abs may
therefore benefit in particular from better accessibility of their
epitope, similar to bnD.3/bnD.3-Fc.
Collectively, our findings strongly suggest that directing anti-
body responses to distinct V3-crown conformations accessible
after CD4 attachment should be feasible, thus opening roads for
developing vaccine strategies to elicit bnD-like V3-crown bnAbs.
Exploiting this knowledge will likely require the design of
appropriate epitope scaffolds to be used as immunogens in order
to channel the polyclonal V3-crown response to the desired
specificity. These responses will likely not be potent, but due to
their high breadth and capacity to recognize an entry state in
which bnAbs targeting prefusion Env have less activity, may add
important functionality to multivalent vaccines.
Methods
Cells. HEK 293-T cells were obtained from the American Type Culture Collection
and TZM-bl cells through the NIH AIDS Reagent Program. Both cell lines were
cultured in DMEM containing 10% FCS. HEK 293 T FreestyleTM suspension
(293 F and Expi293F) cells (Thermo Fisher) for protein expression were main-
tained in suspension in serum-free FreeStyleTM 293F and Expi293F Expression
Media (both from Thermo Fisher) according to the manufacturer’s instructions.
Media were supplemented with Penicillin and Streptomycin and cell lines were
regularly checked for the absence of mycoplasma. No specific cell line authenti-
cation was performed.
Reagents. Properties of monoclonal antibodies used in this study are listed in
Supplementary Supplementary Data 12. We thank the individuals and agencies
listed there as providers of antibodies and/or Ab expression plasmids for this study
either directly or via the NIH AIDS Research and Reference Reagent Program
(NIH ARP). Soluble four-domain CD4 (sCD4)83,84 was provided by W. Olson
(Progenics Pharmaceuticals Inc., Tarrytown, New York, USA).
Peptides and mimetics. CD4M47 was synthesized as described85. Linear V3-
crown peptides and structure-constrained V3-crown mimetic peptides of strains
MN, JR-FL, and BG505.W6M.ENV.C2 were synthesized as described39. The V3
mimetic peptides (Supplementary Fig. 3a, b) were designed to build anti-parallel β-
strands that differ in the formation of inter-strand hydrogen bonds (mimetic
registers). Four structural V3 loop mimetics with different registers were cyclized
by a D-Pro-L-Pro (DPP) dipeptide which stabilizes the hairpin conformation. The
codes of the registers (IY, IF, RY/HY, RF/HF) refer to the amino acids forming the
respective hydrogen bond27,39. The IY register was defined in complex with mAb
F425-B4e837, IF in complex with mAb 221940, RF/HF in complex with mAb 537-
10D38, and RY/HY with mAb 447-52D23. See Supplementary Fig. 3a, b for a full
overview of peptides and mimetics used.
Peptides were biotinylated for use in ELISA, Luminex-based assays, and
Ribosome Display. The linear V3 (MN) peptide was biotinylated on the
N-terminus of a four-glycine N-terminal spacer (Supplementary Fig. 3a). For V3-
IY (MN), a PEG08 linker was introduced between the L-proline in the D-Pro-L-
Pro template of the mimetic and biotin. In the same way, a PEG-4 linker was
introduced between the peptide chain and biotin in all V3 mimetics based on the
sequence of strain BG505 (see also39). In the case of linear V3 (BG505), a
biotinylated PEG-4 linker was attached to an additional N-terminal glutamic acid
residue. All synthetic peptides were ≥95% pure by analytical HPLC and displayed
electrospray MS spectra consistent with the expected masses.
Protein expression, purification and modification
CD4. Two-domain sCD4_183 protein was expressed in E. coli and purified as
described in36.
Env proteins. Codon-optimized sequences of strain JR-FL gp120 wild-type and
V1V2 loop deleted JR-FL86,87 were custom synthesized (GeneArt, Germany). The
BG505-SOSIP source plasmid was kindly provided by J.P. Moore (Weill Cornell
University, New York, USA) and Rogier Sanders (Academic Medical Center,
Amsterdam, Netherlands)44. All Env constructs were fused to a C-terminal AviTag
and cloned into a CMV/R expression vector88 to allow in vitro biotinylation. Env
proteins were produced by transient transfection of HEK 293 T Freestyle suspen-
sion (FS) cells. BG505-SOSIP was expressed by transient transfection using a furin-
expressing helper plasmid at a 3:1 ratio89. All HIV-1 Env proteins were purified
from culture supernatants using Galanthus nivalis lectin resin (Vector Labora-
tories) as described in90. Mono-biotinylation with BirA enzyme was performed
according to the manufacturer (Avidity, Aurora, USA). Proteins were subjected to
Superdex 200 size exclusion chromatography (GE Healthcare, USA) to derive pure
monomer or trimer.
Monoclonal antibody and Fab production. DNA-strings encoding the Fab regions
of Abs 3074, DH753, F425-B4e8, 2219, 10A37 were synthesized (Geneart, Thermo
Fisher Scientific) and cloned into human IgG1, human Igkappa, and human
Iglambda expression vectors (AbVec) using In-Fusion methodology (Takara).
Antibodies were expressed in Expi 293 F cells (Thermo Fisher Scientific) by
transient transfection using TransIT-PRO transfection reagent (Mirus Bio LLC)
according to the manufacturer’s instructions. Supernatants were harvested six days
after transfection, sterile filtered, and supplemented with Protease Inhibitor tablets
(Roche). Antibodies were purified from supernatants using AmMag Protein A
Magnetic Beads (Genscript) according to the manufacturer’s protocol. After elution
of the Abs by 0.1 M glycine, pH 2.7, the eluate was neutralized with 1M Tris, pH
8.7 using a 20th of the eluate volume. Abs were further purified on a HiLoad 16/600
Superdex 200 pg size exclusion chromatography column (GE Healthcare) equili-
brated in 20 mM NaHPO4/NaH2PO4, 100 mM NaCl, pH 6.0, and concentrated to
6 mg/ml (40 µM) using Amicon centrifugal filter units (Millipore).
Fab fragments were prepared from purified mAbs by digestion with papain-
agarose resin (Thermo Fisher Scientific) overnight at 37 °C using 50 µl settled resin/
mg IgG in 20 mM NaHPO4/NaH2PO4, 10 mM EDTA, 20 mM cysteine, pH 7.0. To
remove Fc-fragments and non-digested IgG the reaction was subsequently
incubated with AmMag Protein A magnetic beads (Genscript) overnight at 4 °C,
aiming for a five-fold excess in IgG binding capacity of the beads over the total
input of IgG in the digest. The Fab fragments remaining in the supernatant were
then further purified on a size exclusion chromatrography column (either HiLoad
16/600 Superdex 200 pg or Superdex 200 10/300 GL Increase (both from GE
Healthcare)) equilibrated in either 20 mM NaHPO4/NaH2PO4, 100 mM NaCl, pH
6.0 or PBS, pH 7.4 and concentrated to >16 µM concentration using Amicon
centrifugal filter units (Millipore).
Concentrations of mAbs and Fabs were estimated by measuring OD280 and
applying specific absorption coefficients determined by ProtParam tool
(www.expasy.org) using the respective amino-acid sequences. When converting
concentrations, the molecular weight of the mAbs and Fabs was approximated to
be 150 kDa and 50 kDa, respectively.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27075-0
12 NATURE COMMUNICATIONS |         (2021) 12:6705 | https://doi.org/10.1038/s41467-021-27075-0 | www.nature.com/naturecommunications
DARPin selection by ribosome display. General description of the methodology:
The principal methods of ribosome display, DARPin library design, and DARPin
selection by ribosome display have been previously described in
detail26,28,31,33,91–93. An overview of the methods is provided in Supplementary
Fig. 1.
Ribosome display is an in vitro translation method, where genetic information
(i.e., mRNA) and translated protein remain linked in a ternary complex to the
ribosome33. Since the DARPin sequence is fused to a C-terminal additional
sequence (tether), it emerges from the ribosome and folds, while the C-terminus is
still linked as the peptidyl-tRNA and thus trapped in the ribosome. From the
DARPin library, DARPins of interest are enriched, based on their binding
properties, and simultaneously their coding sequence is obtained from the
mRNA33,91,92. DARPin library screening in combination with ribosome display has
been successfully used in diverse settings26,32,91.
DARPin 5m3_D12 was selected in a previous study27. The selection of novel
V3-crown specific DARPins in the present study was performed by Ribosome
Display (RD) as described previously27,31,32,91,92. In the five RD selections
performed (selections A-E, Fig. 1a and Supplementary Fig. 2), the following
proteins were used as panning targets: (i) the V3-crown mimetic peptide V3-
IY(MN)27, (ii) monomeric gp120 arrested in the CD4-bound state, on which V3 is
highly accessible (JR-FL-gp120 (clade B) in complex with the CD4 mimetic
CD4M4785 and ZM651-gp120 (clade C) in complex with soluble CD4 (sCD4)),
and (iii) BG505-SOSIP (clade A), an engineered trimeric Env gp140 ectodomain on
which access to V3 is restricted by the native-like structural environment8,43,44. For
each of the three target types, five to six RD selection rounds were conducted,
including an off-rate selection round32,70,91, to enrich for high-affinity binders
(Supplementary Fig. 2). In successive RD rounds either a single panning target was
used or two different targets were employed in alternating fashion to promote the
selection of cross-reactive DARPins (Supplementary Fig. 2).
Three versions of starting DARPin libraries were employed, each encoding N3C
DARPins with one N-capping, one C-capping and three internal ankyrin repeats
(Supplementary Figs. 1, 2, and 4a). DARPin selections A and B were conducted
using a first-generation N3C library that encodes N3C DARPins with one N-
capping, one C-capping, and three internal ankyrin repeats29. Selection C used an
improved second-generation N3C library, while selections D and E used a
combination of this latter library with an N3C-loop DARPin library94. In the
second-generation N3C library and N3C-loop DARPin library, additional positions
in both caps were randomized (Supplementary Fig. 4a)26,94, and a more stable
C-cap was used95. The N3C-loop library furthermore contains, in addition to the
randomized positions in the DARPin structure29, the insertion of a flexible loop
with randomized residues94, potentially allowing additional types of target
interaction, similarly to the complementary determining region 3 of Ab heavy
chains96. The second-generation N3C library and N3C-loop DARPin library was
also used in a version without randomized caps.
Manual Ribosome Display selection: Selection A and B were performed as
described in27. Briefly, the respective biotinylated target (Supplementary Fig. 3a
and b) was bound to streptavidin-coupled magnetic microbeads (MyOne-T1
Dynabeads, Invitrogen) and panning of ternary DARPin-mRNA-ribosome
complexes was performed in 1.5 ml microtubes. Heparin, which is commonly used
in RD to prevent non-specific mRNA binding, was omitted from the panning
buffer in all selections because of known interference with gp120 recognition by
DARPins27. Three to five consecutive rounds of RD selection were conducted to
derive pools enriched in target-specific DARPins. One off-rate selection round was
performed to select clones with improved affinity. For this purpose, DARPin-
ribosome complexes were first allowed to bind to the bead-immobilized target,
before a 100- to 1000-fold molar excess of the non-biotinylated target was added as
a competitor for 1-2 h, during which time DARPin binders with a fast off-rate are
lost. The supernatant was removed, beads washed extensively (10-15 times) and a
further RD round without competitor was conducted to amplify the remaining
binders72.
High-throughput Ribosome Display selection (Selections C-E): Bead coupling
was performed as described above. Panning of ternary DARPin-mRNA-ribosome
complexes was performed in 1.5 ml microtubes on a KingFisher Flex magnetic
particle processor (Thermo Fisher Scientific). Five RD rounds were conducted with
decreasing immobilized target concentrations in the first four rounds (250 nM,
125 nM, 50 nM, 5 nM). In the fourth off-rate selection round, a large molar excess
of the soluble target (500 nM) was added to select for high-affinity DARPins. In the
fifth round (referred to as rescue round)32,91, the immobilized target concentration
was increased (50 nM) to amplify the remaining high-affinity DARPins.
DARPin expression and purification. Production of small-scale DARPin batches
(1 ml cultures) for primary screens: DARPin pools obtained after the final RD
round were cloned into pQE30-based expression vectors with an N-terminal his-
tag (selections A and B) or a vector with an N-terminal his-tag and a C-terminal
FLAG®-tag (selections C, D, and E). E. coli XL1 blue bacteria were transformed
with the plasmid pools, individual clones picked (94 clones for selections A and B;
190 clones for selections C, D, and E) and cultures were grown in 1 ml deep-well
plates to OD600= 0.8. Protein expression was induced with 0.5 mM isopropyl-β-D-
1-thiogalactopyranoside (IPTG; Sigma-Aldrich) for 3-4 h. To retrieve DARPins,
bacterial pellets were lysed in 50 μl B-PER II (Thermo Fisher Scientific), shaken for
15 min at 1300 rpm, and then incubated without shaking for 50 min at RT. 1 ml
TBS/0.1% Tween/500 mM NaCl/0.1% BSA (pH 8) was added and the equilibrated
lysate was centrifuged (3000 rpm, 20 min, 4 °C) to remove cell debris. 900 µl of the
supernatant was transferred to a new 96-deep well plate and this crude extract was
stored at −20 °C and used for the primary screening by ELISA.
For primary neutralization screening (see below), DARPins were purified from
400-900 µl bacterial crude extract in 96-well plates using Ni-NTA-coated magnetic
beads (His Mag Sepharose Ni; GE Healthcare). Magnetic beads were equilibrated
with PBS and 20 μl of beads were added to each well containing crude extract and
incubated for 1 h at 1300 rpm. The supernatant was removed using a MagPlex
(Luminex) magnetic plate and beads were washed three times with 300 μl PBS.
DARPins were eluted with 150 μl PBS containing 250 mM imidazole (Sigma
Aldrich). For selections C, D, and E an additional buffer-exchange step was applied,
in which cytotoxic imidazole was removed from DARPin eluates by washing three
times with 150 μl PBS on AcroPrep 96 filter plates (Pall, 3 kDa cut-off). Successful
purification was monitored for randomly selected clones by SDS-PAGE.
Production of large-scale DARPin batches (200 ml - 1 l cultures): These were
produced for all DARPins selected for follow-up experiments. Prior to this
purification, the selected clones from selections A and B were also re-cloned into
the N-terminal his-tag/C-terminal FLAG®-tag vector to allow uniform detection via
the Flag tag in forthcoming experiments. DARPins from large-scale production
batches were purified as described by Ni-NTA affinity chromatography and by SEC
(Size Exclusion Chromatography)97. SEC was performed on an ÄKTA Purifier
system (GE Healthcare) with a Superdex 200 10/300 GL column (GE Healthcare)
and PBS as running buffer. Monomeric fractions were concentrated (Amicon Ultra
Centrifugal Filters, Merck Millipore) and stored at −20 °C. DARPin concentrations
were calculated by measuring the absorbance at 280 nm wavelength on a nanodrop
device (Thermo Fisher Scientific). The specific absorbance coefficients were derived
from the amino acid sequences using the Protparam tool on www.expasy.org. All
clones selected for detailed characterization were checked by Multi-Angle Light
Scattering (MALS) for their oligomerization state. Purified DARPins were
separated on a Superdex 200 10/300 GL size exclusion column coupled to a MALS
detector at the outlet. UV absorption was measured at 280 nm wavelength and
plotted normalized to the peak maximum. DARPins that exhibited a tendency to
form dimers or higher-order aggregates were excluded from further analysis.
Broadly neutralizing DARPins (bnDs) were also expressed as bivalent bnD-Fc
fusions. To this end, the DARPin sequence was fused to the N-terminus of the
coding sequence for the Fc-region of the human IgG1 heavy chain (IGHG1, https://
www.ncbi.nlm.nih.gov/nuccore/NC_000014, REGION: 105741473..105743070),
preserving the hinge region, and cloned into a pcDNA3.1 expression vector.
BnD-Fcs were expressed by transient transfection in 293 F or Expi293F cells and
purified from the supernatant on a protein G affinity chromatography column
equilibrated in 20 mM phosphate buffer, pH 7.0, and eluted with 100 mM glycine,
pH 2.7. The eluate was adjusted to pH 4.0 using 1 M Tris buffer, pH 8.7,
concentrated using an Amicon filter unit (10,000 kDa MWCO, Millipore) and
immediately purified by SEC on a Superdex 200 10/300 GL Increase (GE
Healthcare) column equilibrated in PBS. If immediate purification was not
possible, the eluate was first subjected to a buffer exchange (10 mM Tris, 10%
maltose adjusted to pH 4 with acetic acid) to prevent aggregation of bnD-Fcs.
Detection of DARPin and mAb binding to target proteins and peptides by
ELISA or Luminex assay. 20 nM mono-biotinylated target was immobilized to
white high-binding 96- or 384-well microplates (Corning) pre-coated with 66 nM
Neutravidin (Thermo Fisher Scientific), either overnight at 4 °C or for 1 h at room
temperature (RT), followed by three wash steps with TBST (Tris-buffered saline
containing 0.1% Tween 20 (Sigma Aldrich), pH 7.5). Target Env-proteins were
either probed unliganded or triggered with 50 nM sCD4 or CD4M47. Serial dilu-
tions of purified DARPins were added to microplates in TBSTB (TBST with 0.5%
bovine serum albumin (Sigma Aldrich), pH 7.5). Unbound material was washed off
after 1 h with TBST, and bound DARPins were detected via their FLAG®-tag using
a mouse anti-FLAG® antibody (Sigma Aldrich, clone M2, Cat#F1804 or
Cat#F3165) diluted 1:10’000 in TBSTB. After incubation with alkaline
phosphatase-conjugated polyclonal goat anti-mouse IgG (whole molecule) sec-
ondary antibody (Sigma Aldrich, Cat#A3562) diluted 1:10’000 in TBSTB, a che-
miluminescent substrate (Tropix CDP-star, Thermo Fisher Scientific) was added.
The emission of relative light units was recorded on a Dynex Technologies
Luminometer. Binding of Fc-bnDs was detected on the same instrument using
polyclonal goat anti-human IgG (Fc specific) alkaline phosphatase-conjugated
antibody (Sigma-Aldrich, Cat#A9544) diluted 1:60’000 in TBSTB.
For ELISA screen of selections A and B, B-PER lysed, cell-debris-free DARPin
crude extracts diluted 1:100 in TBSTB were incubated as described above. Bound
DARPins were detected via their His-tag using a monoclonal alkaline phosphatase-
conjugated mouse anti-polyhistidine antibody (Qiagen, clone HIS-1, Cat#A5588)
diluted 1:8,000 in TBSTB.
For ELISA screen of selections C, D, and E, B-PER lysed, cell-debris-free
DARPin crude extracts were diluted 1:100 in PBS / 0.5% BSA. High-binding 384-
well microplates (BioGreiner) were coated with 66 nM Neutravidin (Thermo Fisher
Scientific) in PBS overnight at 4 °C, followed by three wash steps with PBST
(phosphate-buffered saline containing 0.1% Tween 20 (Sigma Aldrich), pH 7.5).
Plates were blocked with PBSTB (PBST supplemented with 0.2% (w/v) BSA) for 1 h
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at 4 °C, followed by three PBST wash steps. Mono-biotinylated target (20 nM) was
added for 1 h at RT and residual target removed by three PBST wash steps.
DARPin crude-extract dilutions were added and allowed to bind the target for 1 h
at 4 °C. FLAG®-tagged DARPins were detected with mouse anti-FLAG® antibody
(Sigma Aldrich, clone M2, Cat# F3165) diluted 1:10’000 in TBSTB and an alkaline
phosphatase-conjugated polyclonal goat anti-mouse IgG (whole molecule)
secondary antibody (Sigma Aldrich, Cat#A3562) diluted 1:10’000 in TBSTB. pNPP
substrate solution (30 mM para-nitrophenylphosphate, 50 nM NaHCO3, 50 nM
MgCl2) was added, and OD 405 nm and 540 nm was measured on a BIO-TEK
Synergy HT Plate Reader.
To measure binding of monoclonal V3-specific antibodies to linear V3 and V3-
crown mimetic peptides we used a customized multiplex bead assay using the
Luminex technology© as described98.
Env pseudovirus production. Neutralization screens conducted in the frame of
this study included sets of five viruses used for the primary screen (Supplementary
Fig. 2), an 18-multi clade virus panel, and an extended 40 multi-clade virus panel.
The latter has been previously used for breadth and fingerprint analyses of bnAbs
and patient plasma47. A full list of Env pseudotyped viruses generated with cor-
responding Env, Genebank entry, clade, and neutralization Tier information is
provided in Supplementary Data 1. The SF162P3N_cl8 env gene99 was a gift from
Cecilia Cheng-Mayer (The Aaron Diamond AIDS Research Center, Rockefeller
University, NY, USA). Env-pseudotyped viruses were prepared by co-transfection
of HEK 293-T cells with plasmids encoding the respective env genes and the
luciferase reporter HIV vector pNLluc-AM as described100.
Env mutants. V1V2-deleted Env mutants were generated as described previously9.
A JR-CSF alanine Env mutant library encompassing 123 mutants in gp120 was
provided by D. Burton16,101,102. All other mutations were generated by site-
directed mutagenesis (QuikChange II kit, Agilent, Santa Clara, USA) according to
the manufacturer’s instructions. A full list of mutants employed for mutational
scanning is depicted in Supplementary Data 7.
Neutralization assay. The neutralization activity of DARPins and mAbs was
evaluated on TZM-bl cells using Env pseudotyped viruses in a 96-well100 or 384-
well47 assay format as described. The input of Env pseudoviruses was chosen to
yield virus infectivity corresponding to 5,000–20,000 relative light units (RLU) in
the absence of inhibitors as measured on a Dynex MLX luminescence reader (96-
well plates). 384-well plates were readout on a Perkin Elmer EnVision Multilabel
Reader. The DARPin or Ab concentrations causing a 50% reduction in viral
infectivity (inhibitory concentration IC50) were calculated by fitting a sigmoid
dose-response curve (variable slope) to the data, using Prism versions 7 or 9
(GraphPad Software). If 50% inhibition was not achieved at the highest or lowest
inhibitor concentration, a ‘greater than’ or ‘less than’ value was recorded. To
control for unspecific effects, all DARPin clones were tested for activity against
MuLV pseudovirus.
Primary neutralization screen of DARPins: As the DARPin yield from 1ml E.
coli cultures is limited, the primary neutralization screen of DARPin pools was
restricted to a single replicate per virus. DARPin preparations from small-scale
purifications were diluted 1:6 in a TZM-bl cell culture medium. Viruses probed in
these initial neutralization screens were chosen based on target antigens employed
in the individual selection and are listed in Supplementary Fig. 2. Percent inhibition
in the presence of DARPin compared to mock-treated controls was recorded for
each DARPin-virus combination.
Secondary neutralization screens on 18- and 40-virus panels were conducted
using purified DARPin preparations with known concentrations. IC50 data
represent geometric means from one to seven independent experiments.
Neutralization screens with a JR-CSF Env mutant panel: 128 JR-CSF mutant
pseudoviruses carrying gp120 point mutations (Supplementary Data 7) were
probed for sensitivity to DARPins and selected mAbs in a two-step screening
approach to detect resistance-conferring mutants. In a first run, all mutant viruses
of the JR-CSF Env panel were screened against all inhibitors. Mutants that passed
in this first screen — a pre-set threshold of resistance (5-fold over IC50 against wt
JR-CSF) against one DARPin — were followed up and retested against all
DARPins, yielding in total at least two independent tests (Supplementary Data 8).
Mutants that showed no effect against any of the inhibitors were not followed up
and hence only tested once.
Sequence analysis of DARPins and Env clones. Sequencing of DARPins and
envelope genes was performed by Sanger sequencing either in-house or at
Microsynth AG (Balgach, Switzerland). All envelope sequence data are based on
HxB2 numbering.
Binding of DARPins to cell-expressed Env. DARPin binding to Env expressed on
293 T cells in the presence and absence of two-domain sCD4-183 was done as
previously described in36. Briefly, 293 T cells were co-transfected with the desired
Env-expression plasmid and the pCMV-rev expression helper plasmid in a 4:1 ratio
and stained 36 h later with biotinylated DARPins. To this end, DARPins were
cloned into the pBD002 expression vector in-frame with an N-terminal AviTag and
a C-terminal polyhistidine-tag. For expression and biotinylation, E. coli XL1 blue
bacteria were co-transformed with the AviTag DARPin vector and with the
pBirAcm expression plasmid coding for the BirA biotinylation enzyme and selected
on agar plates containing 100 µg/ml carbenicillin and 10 µg/ml chloramphenicol.
DARPins were then expressed in TYH-medium supplemented with 0.5% glucose.
Expression was induced at OD600= 0.8 by adding 50 µM IPTG together with
50 µM D-biotin (Applichem). Biotinylated DARPins were purified as described
above on a Ni-NTA column (Qiagen) and by SEC.
Cells were incubated with biotinylated DARPins or DARPin-Fc fusions in the
presence or absence of sCD4-183 for 20 min at RT. Bound DARPins were detected
via APC-Cy7-conjugated streptavidin (BD Biosciences, San Jose, CA, USA;
Cat#554063) diluted 1:500 in FACS-buffer (PBS, 2 mM EDTA, 2% FCS), bound
DARPin-Fc fusions, and mAbs via allophycocyanin (APC) conjugated goat anti-
Human IgG F(ab’)2 (Jackson ImmunoResearch Europe, Ely, UK; Cat#109-136-170)
diluted 1:500 in FACS-buffer on a FACSVerse system (BD Biosciences, San Jose,
CA, USA) and analyzed using FlowJo 10 software (FlowJo LLC, Ashland, OR,
USA). Propidium iodide staining (BD Biosciences, San Jose, CA, USA) diluted
1:500 in FACS-buffer was used to gate for live cells.
Crystallization and protein structure determination. For crystallization, bnD.1,
bnD.2, and bnD.3 were subcloned into plasmid pQiq_H10_3 C which contains a human
rhinovirus 3 C protease-removable 10xhistidine tag. DARPins 63_B7 and 5m3_D12
were produced in pQE30 vectors. DARPins were expressed and Ni-NTA-purified as
described above. For bnD.1, bnD.2 and bnD.3, His-tags were removed by 3C protease
(2% w/w) cleavage overnight while dialyzing against 50mM Tris pH 8, 300mM NaCl.
Uncleaved DARPins and 3 C protease were removed by reverse Ni-NTA chromato-
graphy. Monomeric DARPin fractions were isolated by size-exclusion chromatography
on ÄKTA Pure or Prime systems (GE Healthcare) with HiLoad 16/600 Superdex 75 pg
or Superdex 200 10/300 GL columns (GE Healthcare) and 10mM Tris pH 7.4, 100mM
NaCl (for bnD.1, bnD.2 and bnD.3) or 10mM HEPES pH 7.4, 150mM NaCl (for
63_B7 or 5m3_D12) as running buffer. Monomeric fractions were concentrated
(Amicon Ultra Centrifugal Filters, Merck Millipore) to 20mg/ml and supplemented
with 1.5–2-fold molar excess of V3 mimetic.
Sparse-matrix screens (Hampton Research, Molecular Dimensions, and
Qiagen) in a sitting-drop vapor diffusion format at 4 °C (for bnD.1, bnD.2 and
bnD.3) or 20 °C (63_B7 or 5m3_D12) were used to identify initial crystallization
conditions; focus screens with pH and precipitant gradients were used to refine
initial conditions. Crystals were flash-frozen (liquid N2) in mother liquor
supplemented with 5–15 % ethylene glycol. Data were collected on beam lines
X06DA and X06SA at the Swiss Light Source (Paul Scherrer Institute, Villigen,
Switzerland) using a Pilatus or Eiger detector system (Dectris Ltd).
Data were processed using XDS, XSCALE, and XDSCONV103 (Version October
15, 2015), 5 % of data were set aside to calculate the Rfree value. Initial phases were
obtained by molecular replacement using PHASER (2.6.0)104 with structures of
different N2C and N3C DARPins as search models. Refinement was done using
REFMAC5 (version 5.8.0135)105, BUSTER (version 2.10.1)106, and Phenix-Refine
(version 1.11_2567)107,108, followed by model building in COOT (version 0.8.8)109.
We chose a data cut-off according to Karplus and Diederichs110 that includes more
data than classical approaches. Therefore, the resolutions reported in
Supplementary Data 5 are rather high. For the structures with I/sigma<2 the
resolutions at a cut-off at I/sigma=2 would be approximately 1.9 Å for 63_B7:V3-
IY (PDB ID: 7DNF), 1.67 Å for 63_B7:V3 (PDB ID: 7DNG), 2–2.06 Å for
bnD.1:V3-IF (PDB ID: 7B4T), 1.44–1.48 Å for bnD.2:V3-IF (PDB ID: 7B4V J32),
and 1.9–1.95 Å for bnD.3:V3-IF (PDB ID: 7B4W) as derived by XSCALE.
Structures 7DNF and 7DNG had a relatively low-resolution cut-off (see respective
PDB x-ray structure validation report section 1). To retrieve improved cut-offs we
employed XSCALE as suggested by Karplus et al.111. Cut-offs were applied
according to the results from XSCALE at CC half > 10%. In these calculations the
CC half of 7DNF and 7DNG are 27.3% and 11.7% at a resolution of 1.78 and
1.42 Å, respectively. With the exception of the resolution cutoff, all values listed in
Supplementary Data 5 were generated by the phenix.table_one program and are
consistent with the PDB entry. All V3 mimetics could be completely built into
different electron densities during refinement. Analysis of binding interfaces was
done with LigPlot+ (v1.4.2)112 and QtPISA (version 2.0.4)113. Figures were
prepared with PyMOL (The PyMOL Molecular Graphics System, Version 1.8
Schrödinger, LLC).
Molecular dynamics. Molecular dynamics (MD) simulations were conducted
to characterize the conformational space sampled by the gp120 V3 loop. In total, seven
systems were investigated: a fully glycosylated and a fully deglycosylated structure of
gp120, and five V3 mimetic peptides. The coordinates for the starting structure of gp120
bound to CD4 was extracted from a cryo-electron microscopy structure of gp120 bound
to CD4 and the CCR5 co-receptor (PDB ID: 6meo2). For the fully glycosylated
structure, N-linked mannose-5 glycans (Man5) were modeled onto each sequon, using
the python package Glycosylator 1.0114. All glycans were removed in the fully degly-
cosylated structure. The initial coordinates for the V3 mimetics were extracted from
previously determined structures27. All structures were solvated in a 17Å padding water
box and neutralized with 150mM NaCl (see Table 1 for details).
The simulations were performed with the CHARMM36 force field115,116,
including CMAP corrections for the protein. TIP3P water parameterization was
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used to describe the water molecules. The simulations were carried out using the
ACEMD 3.0 software117. The periodic electrostatic interactions were computed
using particle-mesh Ewald (PME) summation with a grid spacing smaller than 1 Å.
The constant temperature was imposed by using Langevin dynamics with a
damping coefficient of 1.0 ps. The constant pressure of 1 atm was maintained with
the Berendsen barostat. The systems were first minimized by 2000 conjugate
gradient steps, followed by a free molecular dynamics simulation with a hydrogen
mass repartitioning scheme to achieve a timestep of 4 fs. Snapshots from each
simulation were extracted at 1 ns time intervals for structural analysis.
Protein-protein docking. Protein-protein docking was used to investigate the
binding of bnD.2, bnD.3 and six V3 targeting nAbs in context of the full gp120
(F425-B4e8 (PDB ID: 2qsc), 2219 (PDB ID: 2b0s), 3074 (PDB ID: 3mlx), 447-542D
(PDB ID: 4m1d), DH753 (PDB ID: 6mnr), PGT135 (PDB ID: 4jm2)).
For each structure, the co-crystallized V3 peptide was aligned to the different
conformations sampled by the V3 loop during the MD simulation of the fully
glycosylated gp120. The frame with the smallest root-mean-square deviation
(RMSD) between the peptide and the V3 loop was extracted and used as the initial
pose for the docking procedure in the context of an open (CD4 and mAb 17b-
bound) Env trimer structure (PDB ID: 5vn311). In addition, bnD.3 was also docked
to the partially open trimer (PDB ID: 5vn811).
The RosettaDock (2018.33.60351) procedure was used for the protein-protein
docking118. For each structure, 700 poses were generated. The structure with the
lowest energy and an RMSD to the initial pose smaller than 5 Å were considered as
successful docking.
Swiss 4.5 K Screen study population and ethics information. In the current
study, 4,281 plasma samples from HIV-1 infected individuals included in the Swiss
4.5 K Screen13,47 were re-analyzed for binding to V3-crown peptides. A detailed
description of sample/patient selection and study design of the Swiss 4.5 K Screen
has been described previously47. All analyzed plasma samples were derived from
specimens stored in the biobanks of the Swiss HIV Cohort Study (SHCS) and the
Zurich Primary HIV Infection Study (ZPHI). The Swiss HIV Cohort Study (SHCS)
is a prospective, nationwide, longitudinal, non-interventional, observational, clinic-
based cohort with semi-annual visits and blood collections, enrolling all HIV-
infected adults living in Switzerland119. The SHCS, founded in 1988, is highly
representative of the HIV epidemiology in Switzerland as it includes an estimated
53% of all HIV cases diagnosed in Switzerland since the onset of the epidemic, 72%
of all patients receiving ART in Switzerland, and 69% of the nationwide registered
AIDS cases119,120. The SHCS is registered under the Swiss National Science
longitudinal platform: http://www.snf.ch/en/funding/programmes/longitudinal-
studies/Pages/default.aspx#Currently%20supported%20longitudinal%20studies.
Detailed information on the study is openly available on http://www.shcs.ch.
The Zurich Primary HIV Infection Study (ZPHI) is an ongoing, observational,
non-randomized, single-center cohort founded in 2002 that specifically enrolls
patients with documented acute or recent primary HIV-1 infection
(www.clinicaltrials.gov; ID NCT00537966)121.
The SHCS and the ZPHI have been approved by the ethics committee of the
participating institutions (Kantonale Ethikkommission Bern, Ethikkommission des
Kantons St. Gallen, Comité départemental d’éthique des spécialités médicales et de
médicine communautaire et de premier recours, Kantonale Ethikkommission
Zürich, Repubblica e Cantone Ticino - Comitato Ethico Cantonale, Commission
cantonale d’éthique de la recherche sur l'être humain, Ethikkommission beider
Basel for the SHCS and Kantonale Ethikkommission Zürich for the ZPHI) and
written informed consent had been obtained from all participants.
Profiling of the Swiss 4.5 K cohort for V3-crown specific HIV-1 binding
antibodies. We used a customized multiplex bead assay using the Luminex© tech-
nology to measure the plasma IgG1 binding antibody activity to the four V3-crown
mimetic peptides and mimetics in 4,281 individuals included in the Swiss 4.5 K cohort
as described13,98. In addition to the reactivities measured here we utilized binding data
established for three linear V3 peptides (based on BG505, MN, and JR-FL sequences),
JR-FLgp120, BG505gp140, and trimeric BG505-SOSIP determined for the same sam-
ples in a previous study from our group13. Based on the high prevalence of IgG1
antibodies to V3 and the optimal plasma dilution for the binding assay that we pre-
viously established13, we assessed V3-binding IgG1 antibody profiles at a fixed plasma
dilution of 1:6500. Otherwise, the assay was conducted as described13. Recorded binding
intensities were transformed into relative binding data by performing ordinal ranking of
a plasma sample relative to all samples tested on the same day (ranging between 122 to
354 samples tested per day) to rule out intra- and inter-assay variability as
described13,98.
Dissection of neutralization, host, viral and disease parameters that are
linked with V3-IgG1 binding. Data on eight host, viral, and disease parameters of
Swiss 4.5 K individuals was available from our prior studies on this cohort13,47.
Neutralization breadth was used as a categorical response variable. Patients were
defined to have neutralization breadth if their plasma reached cross-, broad- or
elite-neutralization activity score as determined in47,122. Patients with no or weak
neutralization activity scores were categorized as having no neutralization.
We investigated the association of these parameters with V3-IgG1 reactivity by
univariable and multivariable linear regression (using Python 2.7 and its library
statsmodels 0.8.0-3) as described13. Log10 viral load and CD4 level (both measured at
the time of sampling); viral pol diversity123 and infection length were included as
continuous variables. The remaining four factors were used as categorical variables and
analyzed in relation to the reference category (sex: reference male; mode of
transmission: reference men having sex with men (MSM); ethnicity: reference White;
HIV-1 clade: reference clade B, neutralization breadth: reference no neutralization).
The dimensionality reduction method t-SNE124 was used to display the
reactivity with V3 peptides across the entire cohort in Fig. 6b and Supplementary
Fig. 15a. Supplementary Fig. 15b utilizes the same t-SNE plot to visualize the
similarity of V3 peptide-binding responses in the top 105 bnAb plasma samples
identified in the Swiss 4.5 K Screen47. Dominant bnAb specificities in these 105
bnAb plasma samples were previously determined by neutralization
fingerprinting47. The location of bnAb plasma samples with distinct specificities is
visualized on the t-SNE map.
Statistics. Statistical analyses were performed in Python 3.7 using the packages
scipy.stats, statsmodels, and tsne.
The dimensionality reduction method t-SNE was used to display the plasma
samples in two dimensions. As a result of the large cohort size, we used the well-
established Barnes-Hut-SNE approximation (with 1000 iterations and parameters
theta= 0.5 and perplexity= 200) instead of the exact t-SNE method124.
All reported statistical analyses about the V3 reactivity in the Swiss 4.5 K cohort
are of explorative, descriptive nature. We therefore opted, by default, not to
formally adjust for multiple testing since false positives are less of a problem in
explorative studies than false negatives. In addition, owing to the large size of our
cohort, almost all the associations we focus on exhibit a very low p-value, even
lower than a Bonferroni-corrected p-value.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The structural data on DARPin:V3 complexes generated in this study (Fig. 3 and
Supplementary Fig. 9) have been deposited in the Protein Data Bank (PDB) database
under accession codes 7DNE (5m3_D12:V3-IY), 7DNF (63_B7:V3-IY), 7DNG
(63_B7:V3), 7B4T (bnD.1:V3-IF), 7B4U J06 and 7B4V J32 (bnD.2:V3-IF) and 7B4W
(bnD.3:V3-IF). Supplementary Data 5 with corresponding data collection and refinement
statistics is included in the source data file. Other publicly available datasets from the
PDB used in this study (Figs. 3 and 4, Supplementary Figs 3, 10, 11, and 14) are accessible
under PDB IDs 6MEO (CCR5:gp120:sCD4), 5VN8 (b12 Fab:B41-SOSIP trimer), 3GHE
(537-10D Fab:V3), 2QSC (F425-B4e8 Fab:V3), 2B0S (2219 Fab:V3), 3MLX (3074
Fab:V3), 4M1D and 2ESX (447-52D Fab:V3), 6MNR (DH753 Fab:V3), 4JM2 (PGT135
Fab:gp120:17b Fab:sCD4).
Source Data is provided in Supplementary Data. Additional source data related to
Rusert et al. 47, and Kadelka et al.13, can be found online under https://doi.org/10.1038/
nm.4187 and https://doi.org/10.1084/jem.20180246, respectively.
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